CJ Bioscience

CJ Bioscience studies the trillions of microbes living in the human gut, collectively called the microbiome, and uses that research to develop new medicines, genomic analysis tools, and consumer gut-health services.

Its customers include hospitals and medical institutions that use its GUT INSIDE diagnostic service, researchers who use its EzBioCloud microbial genomics platform, and general consumers who use its SMILE GUT gut-health app. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company is actively shifting its business mix away from a pure drug-development model toward a broader portfolio that combines clinical-stage drug candidates with revenue-generating health and wellness services.